“Princeton is a major US life sciences corridor and a leading international research hub with an attractive talent pool, making our decision to remain in this thriving medical and scientific research community an easy one,” Maria Kraus, EVP, corporate development and strategy at Bioclinica told Outsourcing-Pharma.com.
Additionally, the company – which provides medical imaging and eHealth solutions in clinical trials – also has several clients and business partners in the area.
David Herron, president of medical imaging and eHealth solutions who spearheaded the move to the new Princeton location told us the company’s growth has been driven by an increasing use of medical imaging and science-enabled technologies in clinical research in development, testing, and assessing safety and efficacy.
The continuing trend toward outsourcing in drug development has also driven company growth, Kraus, added. “Some of the key areas where we have seen growth is in oncology and more innovative therapies utilizing medical imaging and the increase in protocols for pain management,” she told us.
Additionally, Bioclinica has added adjacent services to its portfolio over the past two years, which has expanded its business into safety and regulatory services, clinical financial lifecycle technologies, site network, and patient recruitment.
“Aside from this, we are experiencing particularly strong growth in our imaging business as imaging is used as a primary endpoint for clinical trials where the scientific and data insights are applied in areas like immunotherapies and precision medicine,” explained Kraus, who added that the company expects to stay on a strong growth trend with this part of the business.